Clover Health Investments (CLOV)
(Delayed Data from NSDQ)
$3.34 USD
-0.02 (-0.60%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $3.35 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.34 USD
-0.02 (-0.60%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $3.35 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
Clover Health Investments, Corp. (CLOV) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Clover Health Investments (CLOV) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Clover Health Investments (CLOV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 125% and 5.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) Q1 Earnings Match Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Info Systems Stocks to Buy as Industry Rebounds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.
Clover Health Investments, Corp. (CLOV) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
by Zacks Equity Research
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.
Clover Health Investments, Corp. (CLOV) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 53.85% and 1.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix
by Zacks Equity Research
Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Consider From a Prospering Industry
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.
Fast-paced Momentum Stock Clover Health Investments, Corp. (CLOV) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Bear of the Day: Icahn Enterprises (IEP)
by Andrew Rocco
IEP stock is getting crushed this year as an inflated NAV, poor fundamentals, and negative headlines present obstacles.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Is Clover Health Investments (CLOV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Pyxis Oncology, Inc. (PYXS) have performed compared to their sector so far this year.
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 21.05% and 7.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Down 22.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Clover Health Investments, Corp. (CLOV)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Clover Health Investments, Corp. (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 48.39% and 3.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?